In a corporate reshuffling, Furen Pharma will acquire Kaifeng Pharma (both companies belong to the Furen Group) for $1.2 billion in a combination of shares and cash and raise $820 million in a secondary offering; Chongqing Fuan Pharma will pay $231 million to acquire Yantai Justaware Pharma, a fellow API company; GenScript Biotech, a US-China provider of life science research products, raised $67.6 million in a Hong Kong IPO; Shanghai Kaibao Pharma invested $20 million in Shanghai Yizhong Biotech, which is developing a coated form of cancer drug paclitaxel; and Sihuan Pharma entered a three-year collaboration with RaQualia Pharma of Japan to develop novel drug candidates for pain relief.
